Get started
Author

Sabrina Trudel

Final results of PX-171–003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)
2009 · S. Jagannath, R. Vij, et al. · Journal of Clinical Oncology · 39
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
2019 · Maxime Jullien, Sabrina Trudel, et al. · Annals of Hematology · 33
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
2019 · Sabrina Trudel, Philippe Moreau, et al. · OncoTargets and Therapy · 29
PDF
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
2019 · Lina Benaniba, Benoit Tessoulin, et al. · BMC Cancer · 17
PDF
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
2019 · Sabrina Trudel, Benoît Tessoulin, et al. · Annals of Hematology · 16
Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia
2024 · Camille Tessier, Richard LeBlanc, et al. · Cancer Medicine · 6
PDF
Efficacy of induction with cybord in newly diagnosed multiple myeloma
2008 · C. B. Reeder, A. K. Stewart, et al. · Journal of Clinical Oncology · 6
Primary or Secondary Plasma Cell Leukemia: Dismal Outcome Despite Modern Treatments
2023 · Camille Tessier, Richard Leblanc, et al. · Blood · 2
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
2025 · Andrée-Anne Pelland, Mathilde Dumas, et al. · Current Oncology · 1
PDF
Pb2146 Single Agent Daratumumab in Very Advanced Relapsed/refractory Multiple Myeloma Patients: a Real‐life Single Center Retrospective Study
2019 · M. Jullien, S. Trudel, et al. · HemaSphere · 1
A377 Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
2009 · S Jagannath, R Vij, et al. · Clinical Lymphoma & Myeloma · 1
A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
2009 · D Reece, E Masih-Khan, et al. · Clinical Lymphoma & Myeloma · 1
Perspective recommendations on geriatric support for older adults with multiple myeloma based on challenges faced by a multidisciplinary team
2026 · Julie Côté, Ploa Desforges, et al. · Frontiers in Oncology
PDF
Patients' perspectives and safety of COVID-19 vaccination among cancer patients: A prospective single-center study.
2022 · Nathalie Daaboul, Melina Boutin, et al. · Journal of Clinical Oncology
Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
2019 · Trudel S, Moreau P, et al. · DOAJ (DOAJ: Directory of Open Access Journals)
Pf651 Pomalidomide, Cyclophosphamide and Dexamethasone in Relapsed/refractory Multiple Myeloma Patients in a Real Life Setting: a Single Center Retrospective Study
2019 · S. Trudel, B. Tessoulin, et al. · HemaSphere
Works count: 16
Citation count: 152
H-index: 6
I10-index: 5
Year
Topic
Type